Xolair (omalizumab) - Roche, Novartis
Fasenra (benralizumab) - AstraZeneca
Dupixent (dupilumab) - Sanofi, Regeneron
Benefits and Harms of Dose Escalation of Inhaled Corticosteroids in Uncontrolled Asthma. (PubMed, J Allergy Clin Immunol Pract) - Oct 10, 2026 - No abstract available 
Journal • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases
http://www.ncbi.nlm.nih.gov/pubmed/42854836
 
Anju T Peters; Antonio Martín; Arnaud Bourdin; Mario Castro; Melissa Iammatteo; Mena Soliman; Njira L Lugogo; Olivier Ledanois; Richard Beasley; William W Busse; Yamo Deniz
 
Oct 10, 2026
 
Prev Next